Small molecule · Agonist of nicotinic acetylcholine receptor · developed by Achieve Life Sciences
Cytisinicline is a small-molecule nicotinic acetylcholine receptor agonist being studied for smoking and vaping cessation. It is formulated as a film-coated tablet containing 1.5 mg cytisine.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07392125 | Phase 3 | Vaping Cessation | Not yet recruiting | ACHV |
| NCT03709823 | Phase 2 | Smoking Cessation | Completed | ACHV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Vaping CessationSmoking Cessation
Updated Oct 3, 2026. Something wrong or missing? Report it on the ACHV page.
See ACHV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ACHV catalysts and pipeline →